PHARMA MAR, S.A. «...1112131415...» Page 13 out of 22 11/11/2021 08:26 PHARMA MAR, S.A. On business and financial situation The Company announces the signature of a license agreement with Lotus Pharmaceutical CO., Ltd. to commercialize lurbinectedin in Taiwan. Register number: 12698 02/11/2021 08:28 PHARMA MAR, S.A. On business and financial situation Pharma Mar’s statement Register number: 12516 28/10/2021 17:36 PHARMA MAR, S.A. Other relevant information - On business and financial situation The Company files third quarter 2021 financial information and announces a conference call with analysts and investors. Register number: 12437 06/10/2021 17:42 PHARMA MAR, S.A. Liquidity and counterparty agreements The Company reports details of the operations of the Liquidity Agreement between 13/07/2021 and 30/09/2021 Register number: 12093 30/09/2021 08:15 PHARMA MAR, S.A. On business and financial situation The Company announces the approval of Zepzelca (lurbinectedin) for the treatment of relapsed stage III or metastatic Small Cell Lung Cancer in Canada. Register number: 11918 22/09/2021 08:27 PHARMA MAR, S.A. On business and financial situation The Company announces the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in Singapore. Register number: 11772 14/09/2021 08:28 PHARMA MAR, S.A. On business and financial situation The Company announces the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in Australia Register number: 11654 01/09/2021 08:26 PHARMA MAR, S.A. On business and financial situation The Company announces the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in the United Arab Emirates Register number: 11447 31/08/2021 16:53 PHARMA MAR, S.A. Board of Directors Regulations La sociedad remite el reglamento del Consejo de Administración Register number: 11435 29/07/2021 16:35 PHARMA MAR, S.A. On corporate governance The Company informs of changes in the composition of the Appointments and Compensation and Sustainability Committee, and in the Audit Committee, as well as the amendments of the Board of Directors Regulations. Register number: 11028 Page 13 out of 22 «...1112131415...»
